Robert Lechleider net worth and biography

Robert Lechleider Biography and Net Worth

Insider of Immunome

Prior to joining Immunome, Dr. Lechleider was the Chief Medical Officer at OncoResponse, where he oversaw the development of the company’s proprietary oncology pipeline. Before OncoResponse, Dr. Lechleider served as the Senior Vice President of clinical development for Seagen, where he was responsible for directing the development of the early and late-stage portfolios, including the successful initial licensing of Padcev® for the treatment of previously treated metastatic urothelial cancer.

Dr. Lechleider began his biotech career at MedImmune (an Astra Zeneca company) and went on to positions of increasing responsibility at Human Genome Sciences and Macrogenics before heading development at Seagen. Prior to his career in biotech, Dr. Lechleider held academic positions where he studied basic cellular and molecular biology.

Dr. Lechleider earned his A.B. from Princeton University and his M.D. from the University of Illinois College of Medicine at Chicago before receiving his clinical residency in internal medicine at Beth Israel-Deaconess Medical Center in Boston, and later in medical oncology at the National Cancer Institute (NCI) in Bethesda.

What is Robert Lechleider's net worth?: The estimated net worth of Robert Lechleider is at least $359.72 thousand as of July 2nd, 2026. Lechleider owns 15,805 shares of Immunome stock worth more than $359,722 as of August 2nd. This net worth evaluation does not reflect any other investments that Lechleider may own. Learn More about Robert Lechleider's net worth.
How do I contact Robert Lechleider?: The corporate mailing address for Lechleider and other Immunome executives is , , . Immunome can also be reached via phone at 610-321-3700 and via email at [email protected]. Learn More on Robert Lechleider's contact information.
Has Robert Lechleider been buying or selling shares of Immunome?: During the last quarter, Robert Lechleider has sold $1,244,100.00 in Immunome stock. Most recently, Robert Lechleider sold 55,000 shares of the business's stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $22.62, for a transaction totalling $1,244,100.00. Following the completion of the sale, the insider now directly owns 15,805 shares of the company's stock, valued at $357,509.10. Learn More on Robert Lechleider's trading history.
Who are Immunome's active insiders?: Immunome's insider roster includes Isaac Barchas (Director), Jean Bienaime (Director), Jack Higgins (Insider), Kinney Horn (Chief Business Officer), Robert Lechleider (Insider), Michael Lefenfeld (Director), Michael Rapp (Director), Max Rosett (CFO), Purnanand Sarma (CEO), Clay Siegall (CEO), Philip Tsai (CTO), Bruce Turner (Insider), and Philip Wagenheim (Director). Learn More on Immunome's active insiders.
Are insiders buying or selling shares of Immunome?: In the last twelve months, Immunome insiders bought shares 7 times. They purchased a total of 85,018 shares worth more than $1,783,233.29. In the last twelve months, insiders at the sold shares 13 times. They sold a total of 994,780 shares worth more than $21,558,079.86. The most recent insider tranaction occured on July, 7th when Director Isaac Barchas sold 16,906 shares worth more than $409,125.20. Insiders at Immunome own 7.2% of the company. Learn More about insider trades at Immunome.
Information on this page was last updated on 7/7/2026.

Robert Lechleider Insider Trading History at Immunome

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/2/2026	Sell	55,000	$22.62	$1,244,100.00	15,805
6/25/2026	Sell	55,000	$19.85	$1,091,750.00	15,805
11/21/2024	Buy	15,805	$9.48	$149,831.40	15,805

Robert Lechleider Buying and Selling Activity at Immunome

Immunome Company Overview

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Today's Range

Now: $22.76

$22.48

$23.70

50 Day Range

MA: $21.20

$17.91

$24.39

2 Week Range

Now: $22.76

$8.66

$27.65

Volume

658,124 shs

Average Volume

1,112,115 shs

Market Capitalization

$2.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07